BZT2312 / Shanghai Cell Therapy Group - LARVOL DELTA

Safety and efficacy of non-viral aPD1-MSLN JL-lightning–CAR-T in advanced malignant mesothelioma in a phase I trial. (ASCO 2025) - P1 | "Non-viral aPD1-MSLN JL-Lightning-CAR-T cells demonstrated robust proliferative capacity, manageable safety profile, and significant anti-tumor potential, offering a promising therapeutic approach for advanced MPM patients."

Clinical • IO biomarker • Metastases • P1 data • Infectious Disease • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Pneumonia • Respiratory Diseases • Solid Tumor • IFNG • IL6 • MSLN

An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd

New P1 trial • Oncology • Solid Tumor